patent on semaglutide Novo Nordisk expiry opens door to cheaper weight-loss drugs in India Post-patent Semaglutide Launch Race Begins

How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test reveals predispositions in key GLP-1 and GIPR pathway variants that may help provide context for how your body's natural satiety signaling works

Cells 2022;11:338

The Precision Peptide Genetic Test ($99 add-on) analyzes variants in GLP1R, MC4R, GIPR, and FTO genes across 14 pathways and 150+ genetic insights that influence how your body absorbs and responds to GLP-1 therapy

Cardiovascular health improvements may reverse

James Byrne, MD, PhD, UI assistant professor of radiation oncology, and his team designed the DRIFT (Drug-Releasing Intravesical Floating Technology) device with the goal of improving the care experience for patients receiving the gem/doce regimen, which was also pioneered at UI Health Care